{"prompt": "['11 July 2019', 'ARGX-113-1704', 'ARGX-113', 'Protocol Version 3.0, Final', '6.', 'TRIAL TREATMENTS', '6.1.', 'Treatments Administered', 'ARGX-113 or matching placebo will be administered weekly for 3 weeks (4 infusions) as an', 'IV infusion (total volume of 125 mL and a dose of 10 mg/kg of body weight) at Visits 1, 2, 3,', 'and 4 of each Treatment Cycle. A variation of 10% of the amount, as planned per protocol,', 'of ARGX-113 administered to the patient, will not be considered an overdose/underdose. In', 'case of a significant (> 10%) change in body weight, the dose will be recalculated.', 'Although ARGX-113 was administered over a period of 2 hours in all the other clinical trials', \"conducted so far, in this trial, for patient's convenience and because no safety concerns are\", 'anticipated based on observations in the other trials, ARGX-113 will be administered over a', 'period of 1 hour. Please refer also to the IB, Section 6.3.', 'Details on infusion rate and time will be given in the IMP management manual (pharmacy', 'manual).', '6.2.', 'Identity of Investigational Medicinal Products', 'The IMP (ARGX-113 or placebo) will be supplied to the Investigator or designated site staff', \"at the investigational site, by and under the responsibility of the Sponsor's designated IMP\", 'supply vendor, who will also provide the Investigator with certificate of analysis, certificate', 'of conformity and European Union Qualified Person (EU QP) release documents.', 'CCI', 'The IMP will be manufactured in accordance with Good Manufacturing Practice (GMP)', 'regulations. Detailed instructions on IMP management on site (including preparation of the', 'IMP) will be included in the IMP management manual (pharmacy manual).', 'The dose will be 10 mg/kg (total dose per IMP infusion is capped at 1200 mg for patients', 'with body weight > 120 kg).', 'argenx BVBA', 'Confidential', 'Page 71 of 110']['11 July 2019', 'ARGX-113-1704', 'ARGX-113', 'Protocol Version 3.0, Final', '6.3.', 'Packaging and Labeling', 'The IMP will be labeled and secondary packed in accordance to local laws and regulatory', 'requirements.', '6.4.', 'Storage of Investigational Medicinal Products', 'The Investigator (or his/her designee) is responsible for the correct and safe storage of the', 'IMP assigned to the clinical site, in a locked, secure storage facility with access limited to', 'those individuals authorized to dispense the IMP, and maintained within the appropriate', 'temperature ranges. The IMP must be stored as specified at delivery and in the original', 'packaging. The placebo and ARGX-113 labeling and packaging will be identical.', 'The IMP must be stored refrigerated (2-8\u00b0C or 35-46\u00b0F) in their secondary packaging, should', 'not be exposed to freezing temperatures, should not be shaken, and should be protected from', 'direct sunlight during storage at the clinical site.', 'Further requirements on temperature logging during storage and information on how to', 'handle temperature excursions can be found in the IMP management manual (pharmacy', 'manual).', '6.5.', 'Method of Assigning Patients to Treatment Group', 'Once the patient has provided informed consent and eligibility has been confirmed by the', 'Sponsor, patients will be stratified according to 3 stratification factors: Japanese VS. non-', 'Japanese patient, AChR-Ab status (seropositive VS. seronegative) and SoC (patients on', 'NSIDs VS. patients not on NSIDs) and randomized at Visit 1 of the first Treatment Cycle via', 'IRT within each stratum to be treated with either ARGX-113 or placebo, on top of their', 'current SoC. A maximum of 20% AChR-Ab seronegative patients will be allowed in the', 'trial. A patient identification number will be allocated, and upon confirmation of eligibility at', 'Visit 1 of the first Treatment Cycle, the site, after confirmation by the Sponsor, will', 'randomize the patient via IRT, which will assign a patient randomization number.', 'Definition: A Japanese patient is defined as a patient whose parents and four grandparents', 'are Japanese, who has the Japanese nationality, was born in Japan, has not lived outside of', 'Japan for a total of > 10 years and currently lives in Japan.', 'The randomization code will be held by the IRT vendor. Patients will be randomized in a 1:1', 'ratio to ARGX-113 or placebo. No blinded trial team members from the Sponsor or the', \"Sponsor's designated blinded CRO team will have access to this randomization code until\", 'after final database lock.', 'argenx BVBA', 'Confidential', 'Page 72 of 110']\n\n###\n\n", "completion": "END"}